Trial Profile
A phase I intraoperative optical imaging study of CLR1502 in patients undergoing lumpectomy surgery
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2015
Price :
$35
*
At a glance
- Drugs CLR 1502 (Primary)
- Indications Breast cancer
- Focus Diagnostic use; Proof of concept
- 11 Jun 2015 According to a company media release, Cellectar Biosciences announced that after review of the company's IND application, the US FDA has determined that CLR1502 will be evaluated as a combination product and assigned to the Center for Devices and Radiological Health (CDRH). The FDA has advised Cellectar that it will need to submit a new IND application for the combination product prior to initiating its planned proof-of-concept trial in breast cancer surgery.
- 07 Nov 2014 New trial record